Investing in Tomorrow's Health
We are a specialist venture investor with a focus on science and technology companies that are posed for rapid growth.
We invest in sectors where innovation is driving exponential growth, and global demand.
We invest in companies with breakthrough technologies & strong leadership, who are on the cusp of a significant value inflection event.
We deploy the capital, resource and expertise required to mitigate risk and accelerate commercial success.
Our Investment Strategy
We invest in Seed and Series A rounds where we can deploy our expertise and capital to help our companies achieve an early inflection point in valuation. We consciously choose investments that create an impact on the lives of patients as well as financial return for our investors.
Our Value Add:
We provide a package of human and capital resources over the life of our investments including:
- – Strong scientific knowledge and frontline healthcare experience
- – Developmental and leadership building experience
- – A carefully built local and global network of healthcare specialists
- – An overriding ambition to succeed in bringing new innovation in healthcare to benefit global recipients
“We are pleased with the performance of Fund 1 and have therefore decided to back Fund 2 as a cornerstone investor.”
– Health Technology Fund II LP
NCLs Health Technology Fund II
NCL has recently launched it Health Technology Fund II. The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.
The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.
Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.
The agony suffered by tragic Diamo Parvez motivated parents Samiya and Naveed to alleviate the suffering of others through the use of an array … Continued
David Vintiner Surgeon Charles Nduka has developed sensor tech to track facial expressions and is currently using it with patients with Parkinson’s. His next … Continued
Trinity College’s new spin-out organisation, Azadyne, has completed a £1.5million funding round for its new approach to the treatment of autoimmune diseases. The Kent … Continued